The role of IMP321 in combination with other immunotherapies (e.g., anti-PD-1 mAb, NCT03625323) or as an adjuvant for cancer vaccines are being explored (NCT00324623, NCT01308294) [66, 67]. Here, PDCD1 is linked to cancer.